Biological Sciences Division
Published July 19, 2018 | Version v1
Patent Open

INHIBITORS OF CACNA1A/ALPHA1A SUBUNIT INTERNAL RIBOSOMAL ENTRY SITE (IRES) AND METHODS OF TREATING SPINOCEREBELLAR ATAXIA TYPE 6

Creators

  • 1. University of Chicago

Contributors

Patent applicant:

Description

The invention provides methods of treating polyglutamine diseases, e.g., spinocerebellar ataxia Type 6, in a subject, comprising administering to the subject an IRES inhibitor in an amount effective for treating the SCA6 in the subject. Also provided herein are the IRES inhibitors, and pharmaceutical compositions comprising the same.

Files

US20180201937.pdf

Files (4.7 MB)

Name Size Download all
md5:4fe84224d348479084de86a05c87fc9e
4.7 MB Preview Download

Additional details

Identifiers

Patent application number
US 201615743560 A
Patent number
US 2018/0201937 A1
Other
oai:uchicago.tind.io:8733

Dates

Patent filed
2016-08-04

UChicago Information

Division(s)
Biological Sciences Division
Department(s)
Neurology